This highlights DPY30 as a critical regulator of epigenetic modifications supporting GSC-driven tumor progression and identifies both DPY30 and PDE4B, a downstream target of DPY30, as potential therapeutic targets in GBM, with the PDE4 inhibitor rolipram as a promising agent [117]. This evidence concerns the gene PDE4A and neoplasm.